We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seattle Genetics Reports Updated Results on Cancer Drug
Read MoreHide Full Article
Seattle Genetics, Inc. and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME). The candidate was assessed as monotherapy treatment for metastatic urothelial cancer (mUC).
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) to target Nectin-4, a cell adhesion molecule which is expressed on many solid tumors.
Seattle Genetics’ share price has increased 23.7% year to date compared with the Zacks classified Medical - Biomedical and Genetics industry’s gain of 2.8%.
The ongoing phase I study is assessing the safety and anti-tumor activity of enfortumab vedotin at escalating doses of 0.5 to 1.25 milligrams per kilogram (mg/kg) weekly for three of every four week cycles. The company announced data from 81 patients who were diagnosed with mUC and a median age of 67 years.
Of these patients, 46% were previously treated with checkpoint inhibitor (CPIs) and 95% had undergone treatment with a platinum-based chemotherapy. The results showed positive antitumor activity and a well-tolerated safety profile in patients with heavily pretreated metastatic urothelial cancer.
Based on the phase I study, Seattle Genetics plans to initiate a registrational monotherapy phase II trial for locally advanced or mUC patients who have been previously treated with CPI therapy in 2017. The company also plans to start a trial evaluating enfortumab vedotin in combination with ? in late 2017 as part of a broad clinical development program.
Recently, Eli Lilly and Company (LLY - Free Report) also announced positive results from a phase III study, RANGE, evaluating its oncology drug, Cyramza (ramucirumab), for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma. The study met its primary end-points and demonstrated an improved progression-free survival (PFS) in patients with the given indication.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seattle Genetics Reports Updated Results on Cancer Drug
Seattle Genetics, Inc. and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME). The candidate was assessed as monotherapy treatment for metastatic urothelial cancer (mUC).
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) to target Nectin-4, a cell adhesion molecule which is expressed on many solid tumors.
Seattle Genetics’ share price has increased 23.7% year to date compared with the Zacks classified Medical - Biomedical and Genetics industry’s gain of 2.8%.
The ongoing phase I study is assessing the safety and anti-tumor activity of enfortumab vedotin at escalating doses of 0.5 to 1.25 milligrams per kilogram (mg/kg) weekly for three of every four week cycles. The company announced data from 81 patients who were diagnosed with mUC and a median age of 67 years.
Of these patients, 46% were previously treated with checkpoint inhibitor (CPIs) and 95% had undergone treatment with a platinum-based chemotherapy. The results showed positive antitumor activity and a well-tolerated safety profile in patients with heavily pretreated metastatic urothelial cancer.
Based on the phase I study, Seattle Genetics plans to initiate a registrational monotherapy phase II trial for locally advanced or mUC patients who have been previously treated with CPI therapy in 2017. The company also plans to start a trial evaluating enfortumab vedotin in combination with ? in late 2017 as part of a broad clinical development program.
Recently, Eli Lilly and Company (LLY - Free Report) also announced positive results from a phase III study, RANGE, evaluating its oncology drug, Cyramza (ramucirumab), for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma. The study met its primary end-points and demonstrated an improved progression-free survival (PFS) in patients with the given indication.
Seattle Genetics, Inc. Price
Seattle Genetics, Inc. Price | Seattle Genetics, Inc. Quote
Zacks Rank and Stocks to Consider
Seattle Genetics carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include VIVUS, Inc. and MEI Pharma, Inc. (MEIP - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all of the four trailing quarters, with an average beat of 233.69%.
MEI Pharma’s estimates narrowed from loss per share of 1 cent to gain per share of 1 cent for 2017 over the last 30 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 66.56%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>